Severe Rhabdomyolysis Associated with the Cerivastatin-Gemfibrozil Combination Therapy: Report of a Case

摘要: Cerivastatin is the new 3rd-generation of synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, 1st drugs choice for treating hypercholesterolemia. potent inhibitor HMG-CoA reductase, it possesses a high affinity liver tissue and decreases plasma low-density lipoprotein cholesterol at microgram doses. produces reductions in 31.3% 36.1% doses 0.3 0.4 mg/day, respectively. It an uncomplicated agent with regard to its pharmacokinetic profile, low potential interaction other drugs, suitability use those impaired renal function. Most statins have been implicated causing rhabdomyolysis, either as mono-therapy or combination agents. We report what our knowledge most profound case yet literature rhabdomyolysis association ceriva-statin-gemfibrozil therapy, both extreme elevation serum creatinine kinase patient's near-paralytic weakness.